COVID-19-associated seizure

Jump to navigation Jump to search

COVID-19 Microchapters

Home

Long COVID

Frequently Asked Outpatient Questions

Frequently Asked Inpatient Questions

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating COVID-19 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Vaccines

Secondary Prevention

Future or Investigational Therapies

Ongoing Clinical Trials

Case Studies

Case #1

COVID-19-associated seizure On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of COVID-19-associated seizure

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on COVID-19-associated seizure

CDC on COVID-19-associated seizure

COVID-19-associated seizure in the news

Blogs on COVID-19-associated seizure

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for COVID-19-associated seizure

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Safakhah, MD[2] Tayebah Chaudhry[3] Syed Musadiq Ali M.B.B.S.[4]

Synonyms and keywords:

Overview

Seizure refers to an episode of symptoms due to abnormally excessive or synchronous neuronal activity in the brain followed by return to normal state. Seizures manifest as abnormal uncontrolled shaking movements that involve much of the body with loss of consciousness, shaking movements of part of the body with variable level of consciousness or a subtle momentary loss of consciousness. As COVID-19 (caused by SARS-Cov2) is now known to have several neurological complications, seizure is one of the complications seen in a few cases so far. Brain waive activity can be seen on EEG to confirm diagnosis since structural changes are very rarely seen on brain imaging. Anti-seizure medications are used for symptomatic treatment of seizure along with treatment of COVID-19.

Historical Perspective

  • First case of seizure in COVID-19 patient was documented by Moriguchi et al[1]. These symptoms were a result of meningitis/encephalitis caused by SARS-Cov-2.

[2] [3] [4]

  • To view the historical perspective of COVID-19, click here.

Classification

Pathophysiology

  • Neurological complications caused by COVID-19 are through direct or indirect pathways. This includes hematogenous pathway, neuronal retrograde dissemination through olfactory bulb, entry into to glial cells and neurons via ACE2 receptor and impairment of gas exchange in lungs leading to anemia, hence increasing anaerobic metabolites in brain resulting in cellular and interstitial edema [5]
  • Seizures in a patient with COVID-19 may be due to primary virus infection or due to reactivation of the latent virus.
  • Infiltration of the brain tissue by the virus and subsequent production of toxins by the virus is one of the several mechanisms that can cause seizures in a COVID-19 patient. [6]
  • Production of inflammatory mediators by the brain may also trigger seizures.
  • Inflammatory cytokines that are released as a result of inflammatory cascade provoked by COVID-19 include interleukin 2,6,7, and 10, TNF-α and granulocyte colony-stimulating factor. Consequently, activation of glutamate receptors by the cytokines causes neuronal hyperexcitability and development of seizures. [6]
Pathophysiology

Causes

The aetiology of seizure regardless whether it is covid-19 or not ,is divided into two categories:

  • 'Provoked seizures : these seizures usually have a temporary trigger such as CNS infection,electrolytes disturbance, withdrawal syndrome,sepsis ,fever, sleep deprivation and stroke.
  • Unprovoked seizures: In this catrgory ,there isn't any obvious cause or precipitating factor .[7]

Differentiating COVID-19-associated seizure from other Diseases

Apart from infectious causes, the differential diagnosis of seizures should include:

Epidemiology and Demographics

  • More data is required to comment on epidemiology and demographics of COVID-19-associated seizure.
  • One study, specifically investigated the neurological manifestations of COVID-19 and documented CNS manifestations in 25% of the patients [headache (13%), dizziness (17%), impaired consciousness (8%), acute cerebrovascular problems (3%), ataxia (0.5), and seizures (0.5%)][8]

Risk Factors

There are no established risk factors for covid-19 associated seizure.

Screening

There is insufficient evidence to recommend routine screening for covid-19 associated seizure.

Natural History, Complications, and Prognosis

The global case fatality rate is currently estimated to be 4.6% according to WHO , 9th,June. .The covid-19 fatality rate depends on several factors such as:

  • patient demographics
  • availability of health care
  • test limitation

Also , the more comorbidities the patient has ,the poorer covid-19 clinical output would be. Some of the prognostic factor of covid-19 are listed as below:

  • Above 65 years old
  • smoking
  • male sex
  • elevated inflammatory markers
  • elevated D-Dimer
  • elevated interleukin 6
  • thrombocytopenia
  • high neutrophil to lymphocyte ratio
  • higher acute physiology and chronic health evaluation score.[9]

Diagnosis

Diagnostic Study of Choice

The diagnosis of COVID-19-associated seizure is made through:

  • Electroencephalogram (EEG, brain waive activity)[10].

Other diagnostic tests include:

History

Symptoms

General symptoms or aura in a patient with include:

Physical Examination

  • Vital Signs: Tachycardia may be present.
  • Postictal drowsiness or confusion.
  • Finding a bite to the side of the tongue, when present, is helpful in making the diagnosis.

Laboratory Findings

Postictal levels of the following may be elevated in a patient with seizures:

  • Prolactin (within 20 minutes after a convulsive event)
  • Lactate (within 1 to 2 hours)
  • Ammonia (within several hours)
  • Creatine kinase (especially 24 to 48 hours postictally)
  • To view the laboratory findings on COVID-19, click here.

Electrocardiogram

  • There are no typical ECG findings associated with seizures in a COVID-19 patient.
  • To view the electrocardiogram findings on COVID-19, click here.

X-ray

  • There are no x-ray findings associated with COVID-19 associated seizure.
  • To view the x-ray finidings on COVID-19, click here.

Echocardiography or Ultrasound

CT scan

  • CT brain may show structural lesions but majority of patients will show nothing.
  • To view the CT scan findings on COVID-19, click here.

MRI

  • MRI brain may show structural lesions but majority of patients will show nothing.
  • To view the MRI findings on COVID-19, click here.

Other Imaging Findings

  • There are no other imaging findings associated with seizure related to COVID-19.
  • To view other imaging findings on COVID-19, click here.

Other Diagnostic Studies

  • To view other diagnostic studies for COVID-19, click here.

Treatment

Medical Therapy

  • Development of seizures in a COVID-19 patient requires urgent treatment.
  • After the cause of seizure is determined, medical therapy should be aimed at treating the cause immediately (for example, hypoxia, fever, metabolic imbalance).
  • Anti-seizure medication (ASM) is often necessary.
  • Anti-epileptics therapy with mannitol has been documented in decreasing cerebral edema[14].
  • For a single seizure less than 5 min rescue treatment with benzodiazepine is not needed. Intravenous ASM are used with caution in COVID-19 patients due to the adverse effects (e.g., Phenytoin, Phenobarbital and Lacosamide in respiratory and cardiac problems) and drug interactions (e.g., Carbamazepine, Phenytoin, Phenobarbital and Valproic acid). [15]
  • Brivaracetam and Levetiracetam have less adverse effects and drug interactions. [15]
  • In patients with more than one seizure (either shorter or longer than 5 min) and in status epilepticus rescue treatment with benzodiazepines in addition to ASM is needed. [15]

Surgery

Surgical intervention is not recommended for the management of COVID-19 associated seizure.

Primary Prevention

There are no established measures for the primary prevention of seizures associated with COVID-19.

Secondary Prevention

There are no established measures for the secondary prevention of seizures associated with COVID-19.

References

  1. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, Ueno M, Sakata H, Kondo K, Myose N, Nakao A, Takeda M, Haro H, Inoue O, Suzuki-Inoue K, Kubokawa K, Ogihara S, Sasaki T, Kinouchi H, Kojin H, Ito M, Onishi H, Shimizu T, Sasaki Y, Enomoto N, Ishihara H, Furuya S, Yamamoto T, Shimada S (May 2020). "A first case of meningitis/encephalitis associated with SARS-Coronavirus-2". Int. J. Infect. Dis. 94: 55–58. doi:10.1016/j.ijid.2020.03.062. PMC 7195378 Check |pmc= value (help). PMID 32251791 Check |pmid= value (help).
  2. Hepburn, Madihah; Mullaguri, Naresh; George, Pravin; Hantus, Stephen; Punia, Vineet; Bhimraj, Adarsh; Newey, Christopher R. (2020). "Acute Symptomatic Seizures in Critically Ill Patients with COVID-19: Is There an Association?". Neurocritical Care. doi:10.1007/s12028-020-01006-1. ISSN 1541-6933.
  3. {{https://www.sciencedirect.com/science/article/pii/S1059131120301151}}
  4. {{https://onlinelibrary.wiley.com/doi/full/10.1111/epi.16524}}
  5. {{https://pubmed.ncbi.nlm.nih.gov/32458193/}}
  6. 6.0 6.1 Karimi, Narges; Sharifi Razavi, Athena; Rouhani, Nima (2020). "Frequent Convulsive Seizures in an Adult Patient with COVID-19: A Case Report". Iranian Red Crescent Medical Journal. 22 (3). doi:10.5812/ircmj.102828. ISSN 2074-1804.
  7. {{https://www.ncbi.nlm.nih.gov/books/NBK430765/}}
  8. Mao, Ling; Jin, Huijuan; Wang, Mengdie; Hu, Yu; Chen, Shengcai; He, Quanwei; Chang, Jiang; Hong, Candong; Zhou, Yifan; Wang, David; Miao, Xiaoping; Li, Yanan; Hu, Bo (2020). "Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China". JAMA Neurology. 77 (6): 683. doi:10.1001/jamaneurol.2020.1127. ISSN 2168-6149.
  9. {{ https://bestpractice.bmj.com/topics/en-gb/3000168/prognosis }}
  10. Haines S, Caccamo A, Chan F, Galaso G, Catinchi A, Gupta PK (2020). "Practical Considerations When Performing Neurodiagnostic Studies on Patients with COVID-19 and Other Highly Virulent Diseases". Neurodiagn J. 60 (2): 78–95. doi:10.1080/21646821.2020.1756132. PMC 7212538 Check |pmc= value (help). PMID 32374647 Check |pmid= value (help).
  11. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM (2018). "Neurologic Alterations Due to Respiratory Virus Infections". Front Cell Neurosci. 12: 386. doi:10.3389/fncel.2018.00386. PMC 6212673. PMID 30416428.
  12. Li YC, Bai WZ, Hashikawa T (2020). "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients". J Med Virol. 92 (6): 552–555. doi:10.1002/jmv.25728. PMC 7228394 Check |pmc= value (help). PMID 32104915 Check |pmid= value (help).
  13. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K (2020). "Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review". Clin Neurol Neurosurg. 194: 105921. doi:10.1016/j.clineuro.2020.105921. PMC 7227498 Check |pmc= value (help). PMID 32422545 Check |pmid= value (help).
  14. Ye M, Ren Y, Lv T (April 2020). "Encephalitis as a clinical manifestation of COVID-19". Brain Behav. Immun. doi:10.1016/j.bbi.2020.04.017. PMC 7146652 Check |pmc= value (help). PMID 32283294 Check |pmid= value (help).
  15. 15.0 15.1 15.2 Asadi-Pooya AA (July 2020). "Seizures associated with coronavirus infections". Seizure. 79: 49–52. doi:10.1016/j.seizure.2020.05.005. PMC 7212943 Check |pmc= value (help). PMID 32416567 Check |pmid= value (help).


Template:WikiDoc Sources